PHILIP MULLER: Open Payments
NPI 1891756128 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,724 in 103 payments from 17 companies in 2025. Trend: 2023 $1,285 · 2024 $1,002 · 2025 $1,724
Food & beverage: $1,723Education: $1
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 16 | $341 |
| Otsuka America Pharmaceutical, Inc. | 16 | $287 |
| E.R. Squibb & Sons, L.L.C. | 14 | $176 |
| Alkermes, Inc. | 8 | $169 |
| Lundbeck LLC | 7 | $150 |
| ABBVIE INC. | 16 | $150 |
| Teva Pharmaceuticals USA, Inc. | 6 | $102 |
| Janssen Pharmaceuticals, Inc | 4 | $79 |
| Neurocrine BioSciences, Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
Products named: REXULTI, HETLIOZ, COBENFY, ARISTADA, VRAYLAR, FANAPT, AUSTEDO XR, INGREZZA.
Industry payments across IA — which companies pay providers there.
